CN Patent

CN102985070A — 用于hrt的极低剂量的固体口服剂型

Assigned to Bayer Pharma AG · Expires 2013-03-20 · 13y expired

What this patent protects

本发明涉及用于激素替代疗法（HRT）的极低剂量的剂型。更具体地，本发明涉及包含约0.5mg雌二醇和约0.25mg屈螺酮、以及至少一种可药用赋形剂的固体口服剂型。尽管E2和DRSP剂量极低，令人惊讶地发现高比例的患中度至重度热潮红的妇女实际上响应本治疗。因此，本发明的剂型可被用作维持HRT或当HRT开始时可已被使用。

USPTO Abstract

本发明涉及用于激素替代疗法（HRT）的极低剂量的剂型。更具体地，本发明涉及包含约0.5mg雌二醇和约0.25mg屈螺酮、以及至少一种可药用赋形剂的固体口服剂型。尽管E2和DRSP剂量极低，令人惊讶地发现高比例的患中度至重度热潮红的妇女实际上响应本治疗。因此，本发明的剂型可被用作维持HRT或当HRT开始时可已被使用。

Drugs covered by this patent

Patent Metadata

Patent number
CN102985070A
Jurisdiction
CN
Classification
—
Expires
2013-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.